NEW YORK ─ PixCell Medical on Tuesday announced that it has inked an exclusive distribution agreement with Katalyst Diagnostics, a new division of Katalyst Laboratories, to distribute PixCell's HemoScreen complete blood count (CBC) analyzer in the UK and Ireland.
Financial and other terms of the deal were not disclosed.
London-based Katalyst Laboratories is a provider of molecular diagnostic testing services to private healthcare and travel hubs, an authorized distributor of molecular diagnostic test platforms, and a business-to-business supplier of COVID-19 PCR and antigen tests in the UK.
Katalyst formed a new division, Katalyst Diagnostics, to distribute artificial intelligence-based technologies and products across the UK and Ireland as part of the growing need for quality POC diagnostics, and HemoScreen is a crucial element of its strategy, according to Yokneam Ilit, Israel-based PixCell.
HemoScreen, a five-part differential CBC analyzer, has been cleared by the US Food and Drug Administration, CE-marked, and approved by Australia's Therapeutic Goods Administration for point-of-care use.
PixCell said HemoScreen provides laboratory-level diagnostic testing accuracy from a single fingerprick of blood within five minutes, allowing healthcare professionals to make rapid decisions.
Last July, PixCell Medical announced an exclusive distribution agreement with Gamidor Diagnostics to distribute HemoScreen in Israel.